Investment Thesis
Odyssey Health exhibits critical financial distress with zero revenue generation, negative stockholders' equity of -$10.6M, and ongoing cash burn of -$576.3K in free cash flow. The company's liquidity crisis (current ratio 0.06x) and inability to service debt (interest coverage -1.1x) present existential viability concerns. Without immediate operational turnaround and significant capital infusion, the company faces imminent insolvency.
Strengths
- Retains $616.3K in cash providing limited runway for operations or restructuring
- Relatively small asset base of $721.3K allows for potential strategic alternatives
- Operates in established medical device sector with addressable market opportunity
Risks
- Zero revenue generation indicating non-operational business status
- Negative stockholders equity of -$10.6M representing technical insolvency
- Severe liquidity crisis with current ratio of 0.06x unable to cover short-term obligations
- Negative operating cash flow of -$568.3K with estimated 12-month cash runway remaining
- Interest coverage ratio of -1.1x indicates inability to service $2.0M long-term debt
- No insider activity over 90 days suggests absence of management confidence or initiative
Key Metrics to Watch
- Achievement of revenue generation and operational restart timeline
- Monthly operating cash flow trends and cash depletion rate
- Debt restructuring or capital infusion announcements
- Stockholders equity recovery path and recapitalization milestones
Financial Metrics
Revenue
0.0
Net Income
-4.1M
EPS (Diluted)
$-0.04
Free Cash Flow
-576.3K
Total Assets
721.3K
Cash
616.3K
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
N/A
ROA
-566.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
0.06x
Quick Ratio
0.06x
Debt/Equity
N/A
Debt/Assets
651.4%
Interest Coverage
-1.12x
Long-term Debt
2.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T13:09:22.863471 |
Data as of: 2026-01-31 |
Powered by Claude AI